N1和N2淋巴结转移中的微乳头和实性组织学模式是II至III期肺腺癌患者不良预后的独立因素
研究纳入2000至2012年间接受肺叶切除术的病理II至III期伴N1或N2淋巴结转移的肺腺癌患者360例,分析淋巴结转移中微乳头(MIP)和/或实性(SOL)模式与总生存(OS)、肺癌特异性累积死亡发生率(LC-CID)及累积复发发生率(CIR)的关系。结果显示淋巴结转移中存在MIP/SOL模式与更短OS、更高LC-CID和更高CIR相关,且为不良预后的独立因素。
要点
- 淋巴结转移中MIP/SOL模式与吸烟史、肿瘤坏死及气腔播散发生率更高相关。
- 淋巴结转移有MIP/SOL者5年OS为40%,无者为63%(p=0.03)。
- 多变量分析显示淋巴结转移MIP/SOL与OS(HR=1.81)、LC-CID(HR=3.10)和CIR(HR=2.06)独立相关。
核心结论
- N1或N2淋巴结转移中的MIP/SOL组织学模式与II至III期肺腺癌患者更差结局相关,可据此对高危患者进行分层。
研究设计与样本
- 分析2000至2012年间接受肺叶切除术的病理II至III期伴N1或N2淋巴结转移的肺腺癌患者360例。
- 比较淋巴结转移中有与无MIP/SOL模式患者的总生存(OS)、肺癌特异性累积死亡发生率(LC-CID)和累积复发发生率(CIR)。
- 采用多变量Cox回归分析量化MIP/SOL模式与结局的关联。
主要发现
- 淋巴结转移有MIP/SOL者吸烟史发生率更高(p=0.004),肿瘤坏死发生率更高(p=0.013),气腔播散发生率更高(p<0.0001)。
- 淋巴结转移有MIP/SOL者原发肿瘤中MIP或SOL prevalence更高(p<0.0001)。
- 淋巴结转移有MIP/SOL者5年OS为40%(95%CI 29%-56%),无者为63%(95%CI 48%-83%),p=0.03。
- 淋巴结转移有MIP/SOL者5年LC-CID为43%(95%CI 29%-56%),无者为14%(95%CI 4%-29%),p=0.013。
- 淋巴结转移有MIP/SOL者5年CIR为65%(95%CI 50%-77%),无者为43%(95%CI 25%-60%),p=0.057。
关键数值与推荐
- 多变量分析:OS的HR=1.81(95%CI 1.00-3.29),p=0.05。
- 多变量分析:LC-CID的HR=3.10(95%CI 1.30-7.37),p=0.01。
- 多变量分析:CIR的HR=2.06(95%CI 1.09-3.90),p=0.026。
临床怎么用
- 原文结论指出淋巴结转移中的MIP/SOL组织学模式可用于对II至III期肺腺癌高危患者进行分层。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: High-grade histologic patterns are associated with poor prognosis in patients with primary nonmucinous lung adenocarcinoma (ADC). We investigated whether the presence of micropapillary (MIP), solid (SOL), or both patterns in lymph node (LN) metastases has prognostic value. METHODS: Patients who underwent lobectomy for pathologic stages II to III lung ADC with N1 or N2 LN metastases (N = 360; 2000-2012) were analyzed. We assessed overall survival (OS), lung cancer-specific cumulative incidence of death (LC-CID), and cumulative incidence of recurrence (CIR) between patients with and without MIP/SOL patterns in LN metastases. Multivariable Cox regression analysis was used to quantify the association between MIP/SOL patterns and outcomes. RESULTS: MIP and SOL in LN metastases were associated with a higher incidence of smoking history (p = 0.004), tumor necrosis (p = 0.013), and spread of tumor through air spaces (p < 0.0001), a higher prevalence of MIP or SOL in the primary tumor (p < 0.0001), shorter OS (5-y OS, 40% [95% confidence interval or CI: 29%-56%] versus 63% [48%-83%] for no MIP/SOL in LNs, p = 0.03), higher LC-CID (5-y, 43% [29%-56%] versus 14% [4%-29%], p = 0.013), and higher CIR (5-y, 65% [50%-77%] versus 43% [25%-60%], p = 0.057). MIP and SOL in LN metastases were independently associated with poor outcomes: OS (hazard ratio [HR] = 1.81 [95% CI: 1.00-3.29], p = 0.05), LC-CID (HR = 3.10 [1.30-7.37], p = 0.01), and CIR (HR = 2.06 [1.09-3.90], p = 0.026). CONCLUSIONS: MIP/SOL histologic patterns in N1 or N2 LN metastases are associated with worse outcomes in patients with stages II to III lung ADC. MIP/SOL histologic patterns in LN metastases can stratify patients with high-risk stages II to III lung ADC.
引用
- Li Y, Byun AJ, Choe JK, et al. Micropapillary and Solid Histologic Patterns in N1 and N2 Lymph Node Metastases Are Independent Factors of Poor Prognosis in Patients With Stages II to III Lung Adenocarcinoma. J Thorac Oncol. 2023. PMID: 36681298. doi:10.1016/j.jtho.2023.01.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。